All In Biotech

Drug Trial Radar · NCT06847724

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

A Randomized, Double-blind, Parallel-group Study to Compare the Pharmacokinetics, Efficacy, Pharmacodynamics, Safety, and Immunogenicity of CYB704 (Proposed Ocrelizumab Biosimilar) and Ocrevus® in Participants With Relapsing Multiple Sclerosis (RMS) [STRIVE-MS].

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

183

Actual

Start

Jun 10, 2025

Primary completion

Nov 3, 2026

Study completion May 2027

Sponsor

Lead sponsor
SandozNovartis (NVS)
Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)? * Does have CYB704 the same treatment effect and side effects as the reference product? Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will: * Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU) * Visit the clinic for at least 15 treatment visits, checkups and tests * Will undergo regular magnetic resonance imaging (MRI) examinations

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • CYB704Biological

    Intravenous Infusion

  • Ocrevus-EUBiological

    Intravenous Infusion

  • Ocrevus-USBiological

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration time curveTime frame: Week 1 - 3, week 3 - 25

Locations

41 sites in 8 countries. Site status is shown where the registry gives one.

  • Sandoz Investigational Site

    Maitland, Florida

  • Sandoz Investigational Site

    Ormond Beach, Florida

  • Sandoz Investigational Site

    Banja Luka, Bosnia and Herzegovina

  • Sandoz Investigational Site

    Bihać, Bosnia and Herzegovina

  • Sandoz Investigational Site 2

    Sarajevo, Bosnia and Herzegovina

  • Sandoz Investigational Site

    Sarajevo, Bosnia and Herzegovina

  • Sandoz Investigational Site

    Pleven, Bulgaria

  • Sandoz Investigational Site 2

    Plovdiv, Bulgaria

  • Sandoz Investigational Site

    Plovdiv, Bulgaria

  • Sandoz Investigational Site 2

    Sofia, Bulgaria

  • Sandoz Investigational Site 3

    Sofia, Bulgaria

  • Sandoz Investigational Site 4

    Sofia, Bulgaria

  • Sandoz Investigational Site 5

    Sofia, Bulgaria

  • Sandoz Investigational Site

    Sofia, Bulgaria

  • Sandoz Investigational Site

    Varaždin, Croatia

  • Sandoz Investigational Site

    Zagreb, Croatia

  • Sandoz Investigational Site

    Rustavi, Georgia

  • Sandoz Investigational Site 2

    Tbilisi, Georgia

  • Sandoz Investigational Site 3

    Tbilisi, Georgia

  • Sandoz Investigational Site 4

    Tbilisi, Georgia

  • Sandoz Investigational Site 5

    Tbilisi, Georgia

  • Sandoz Investigational Site 6

    Tbilisi, Georgia

  • Sandoz Investigational Site 7

    Tbilisi, Georgia

  • Sandoz Investigational Site 8

    Tbilisi, Georgia

  • Sandoz Investigational Site

    Tbilisi, Georgia

  • Sandoz Investigational Site

    Shtip, North Macedonia

  • Sandoz Investigational Site

    Skopje, North Macedonia

  • Sandoz Investigational Site

    Bydgoszcz, Poland

  • Sandoz Investigational Site 2

    Katowice, Poland

  • Sandoz Investigational Site

    Katowice, Poland

  • Sandoz Investigational Site

    Lodz, Poland

  • Sandoz Investigational Site 2

    Lublin, Poland

  • Sandoz Investigational Site

    Lublin, Poland

  • Sandoz Investigational Site

    Nowa Sól, Poland

  • Sandoz Investigational Site 2

    Poznan, Poland

  • Sandoz Investigational Site

    Poznan, Poland

  • Sandoz Investigational Site

    Szczecin, Poland

  • Sandoz Investigational Site

    Warsaw, Poland

  • Sandoz Investigational Site

    Zabrze, Poland

  • Sandoz Investigational Site

    Belgrade, Serbia

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.